Weight loss candidate drug nimacimab safety approved. Skye (SKYE.US) stock price soared 11%.

Skye Bioscience's stock price soared 11%, benefiting from the safety differences between its weight loss candidate drug nimacimab and novo-nordisk a/s's monlunabant.

Zhitong FinanceSep 24 03:26 ET

Sector Update: Health Care Stocks Retreat Late Afternoon

MT NewswiresSep 23 16:03 ET

Skye Stock Rallies 22% Following Weight-loss Drug Update

Seeking AlphaSep 23 12:27 ET

Structure Therapeutics Shares Are Trading Higher After Morgan Stanley Initiated Coverage on the Stock With an Overweight Rating and Announced a $118 Price Target.

BenzingaSep 23 09:14 ET

Cantor Fitzgerald Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $65

Moomoo NewsSep 23 08:33 ET · Ratings

Cantor Fitzgerald Sticks to Their Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)

TipRanksSep 23 07:56 ET · Ratings